AI drug developer Isomorphic raises $5 billion in Series C round
Alphabet-backed Isomorphic Labs raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital as it works to move its first drug candidates into clinical trials. The company did not disclose its valuation.
1. Funding round
Isomorphic Labs said it raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz and other new investors joined, while Alphabet made a significant investment; existing backers including Thrive Capital, MGX and GV also participated. The company declined to share its valuation.
2. Drug development
The company is developing its IsoDDE drug design engine to design drugs, predict their properties and refine them before scientists choose candidates to make and test. Isomorphic said it has seen positive pre-clinical results in internal oncology and immunology programs and with partners, setting the stage for clinical entry. CEO Demis Hassabis said the funding would accelerate its work on biology models, disease understanding and therapeutic programs.
3. Earlier financing
The funding comes about six months after Isomorphic raised $2.1 billion in a Series B round led by Thrive Capital. The company lists Novartis, Eli Lilly and Johnson & Johnson as partners.





